Administration of the first dose of mRNA-based COVID-19 vaccines increased IFN-γ in response to AG1 compared with the baseline up to a median 0.18 (interquartile range, IQR 0.07–0.57) IU/mL and 2.11 (IQR 0.80–3.63) IU/mL for uninfected and infected groups, respectively (Fig. 2a and Table S1). The gene discussed is IFNG; the disease is COVID-19.